2nd Quarter - Report

EMERGENT BIOSOLUTIONS INC. for EMERGENT BIOSOLUTIONS INC

Firm
Client
Income
—
Expenses
$730,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Homeland Security HOM

P.L. 115-5 - American Recovery Act of 2009 -implementation of provisions relating to biodefense funding; Department of Labor, Health & Human Services and Education Appropriations Act of 2011 - all provisions relating to development, acquisition and stockpiling of biodefense vaccines. Department of Homeland Security Appropriations Act, 2011 - all provisions relating to the development, acquisition and stockpiling of biodefense vaccines; S. 1649 and H.R. 5498 - WMD Prevention and Preparedness Act of 2009 - all provisions relating to the acquisition and stockpiling of biodefense vaccines; Implementation of the Biomedical Advanced Research & Development Authority (BARDA) & Project BioShield relating to stockpiling of biodefense vaccines.

LobbyistCovered position, as disclosed
ASHLEY BRATICH —
CHRIS FRECH —
ALLEN SHOFE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1649 (111th), H.R. 5498 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.